PR CENTER
NEWGLAB PR Center
One of the missions of NewG Lab Pharma
(NGLP) will be to develop novel anticancer
therapeutics that extend the life of cancer patients
without compromising the quality of life.
- PR Center
- NEWS
One of the missions of NewG Lab Pharma
(NGLP) will be to develop novel anticancer
therapeutics that extend the life of cancer patients
without compromising the quality of life.
As of May 1, 2020, NewG Lab Pharma received a letter from the FDA for Orphan drug designation (ODD) for "treatment of stage IIb-IV melanoma".
As a result, NewG Lab Pharma acquired Orphan drug status for liver cancer, intra-hepatic bile duct cancer and melanoma.
NewG Lab Pharma plans to start the FDA Phase 1 clinical trial in 2021.